cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.19940584.v1
title: Evaluation of the insecticide susceptibility profile in Cimex lectularius (Hemiptera: Cimicidae) in Belo Horizonte (Brazil)

description: Abstract INTRODUCTION: Since 2013, major Cimex lectularius infestations have been detected in public shelters in Belo Horizonte (Brazil). Due to this, insecticide resistance has been investigated as one of the possible causes for the failure to control bedbugs. METHODS: Cimicids were subjected to bioassays according to the World Health Organization recommendations using deltamethrin and all commercial insecticides available for control of Cimex in Brazil. RESULTS: Cimicids were deltamethrin resistant and presented indicative of resistance to other insecticides, except for propoxur 1%. CONCLUSIONS: The commercial insecticides have a limited effect on bedbug populations, which may justify the unsatisfactory control observed in the shelters studied.
DOI: 10.6084/m9.figshare.19940586.v1
title: Long-Term Persistence of Serum-Specific Anti-Chikungunya IgM Antibody - A Case Series of Brazilian Patients

description: Abstract The persistence of serum-specific anti-chikungunya IgM antibodies (CHIKV-IgM) can vary after chikungunya fever (CHIK) infection. However, the factors related to its production are not yet known. We described a case series drawn up from data collected from 57 patients between 12 and 36 months after the acute phase of CHIK infection in Northeastern Brazil. CHIKV-IgM was detectable in 7/57 (12.3%) patients after 28.3 months of infection. No frequency differences in chronic musculoskeletal manifestations and underlying conditions were detected between patients with or without CHIKV-IgM. CHIKV-IgM was detected for up to 35 months in Brazilian patients after CHIK infection.
DOI: 10.6084/m9.figshare.19940586
title: Long-Term Persistence of Serum-Specific Anti-Chikungunya IgM Antibody - A Case Series of Brazilian Patients

description: Abstract The persistence of serum-specific anti-chikungunya IgM antibodies (CHIKV-IgM) can vary after chikungunya fever (CHIK) infection. However, the factors related to its production are not yet known. We described a case series drawn up from data collected from 57 patients between 12 and 36 months after the acute phase of CHIK infection in Northeastern Brazil. CHIKV-IgM was detectable in 7/57 (12.3%) patients after 28.3 months of infection. No frequency differences in chronic musculoskeletal manifestations and underlying conditions were detected between patients with or without CHIKV-IgM. CHIKV-IgM was detected for up to 35 months in Brazilian patients after CHIK infection.
DOI: 10.6084/m9.figshare.19940589.v1
title: Dengue fever as a potential cause of sickle cell intrahepatic cholestasis: A report of two cases

description: Abstract Sickle cell intrahepatic cholestasis is a potentially fatal syndrome characterized by jaundice, painful hepatomegaly, and organ dysfunction. Two cases of sickle cell intrahepatic cholestasis associated with dengue fever were described. Endothelial damage/dysfunction is a mechanism involved in severe hepatobiliary complications related to sickle cell diseases. However, the reasons for the lack of increase in the admission of patients with sickle cell disease having severe acute hepatobiliary complications triggered by endothelial damage/dysfunction due to dengue fever remain unknown. This study describes the first association between sickle cell intrahepatic cholestasis and dengue fever.
DOI: 10.6084/m9.figshare.19940589
title: Dengue fever as a potential cause of sickle cell intrahepatic cholestasis: A report of two cases

description: Abstract Sickle cell intrahepatic cholestasis is a potentially fatal syndrome characterized by jaundice, painful hepatomegaly, and organ dysfunction. Two cases of sickle cell intrahepatic cholestasis associated with dengue fever were described. Endothelial damage/dysfunction is a mechanism involved in severe hepatobiliary complications related to sickle cell diseases. However, the reasons for the lack of increase in the admission of patients with sickle cell disease having severe acute hepatobiliary complications triggered by endothelial damage/dysfunction due to dengue fever remain unknown. This study describes the first association between sickle cell intrahepatic cholestasis and dengue fever.
DOI: 10.6084/m9.figshare.19435349
title: Dreadnoughtus Elbow Model 2

description: This is the simulation file (Adams MSC) for <i>Dreadnoughtus </i>with our second reconstruction of articular cartilage.
DOI: 10.6084/m9.figshare.19435358
title: Dreadnoughtus Elbow Model 3

description: This is the simulation file (Adams MSC) for <i>Dreadnoughtus </i>with our third reconstruction of articular cartilage.
DOI: 10.6084/m9.figshare.19435358.v1
title: Dreadnoughtus Elbow Model 3

description: This is the simulation file (Adams MSC) for <i>Dreadnoughtus </i>with our third reconstruction of articular cartilage.
DOI: 10.5281/zenodo.6599269
title: Quantification of transgene expression in GSH AAVS1 with a novel CRISPR/Cas9 based approach reveals high transcriptional variation

description: Inderbitzin, Loosli and colleagues employ a novel method to construct and extensively characterize DNA barcode libraries and apply CRISPR/Cas9 technology for targeted insertion into the safe harbor gene AAVS1 in Jurkat cells. This technique revealed high fluctuations in gene expression in AAVS1, spanning over two logs.
DOI: 10.6084/m9.figshare.19427012
title: Alligator Cartilage Reconstructed Model

description: This is the simulation file (Adams MSC) for our model of the alligator elbow with its cartilage reconstructed as we did in our <i>Dreadnoughtus </i>models.
DOI: 10.6084/m9.figshare.19435340
title: Dreadnoughtus Elbow Model 1

description: This is the simulation file (Adams MSC) for <i>Dreadnoughtus </i>with our first reconstruction of articular cartilage.
DOI: 10.6084/m9.figshare.19435349.v1
title: Dreadnoughtus Elbow Model 2

description: This is the simulation file (Adams MSC) for <i>Dreadnoughtus </i>with our second reconstruction of articular cartilage.
DOI: 10.6084/m9.figshare.19426961
title: Turkey Original Cartilage Model

description: This is the simulation file (Adams MSC) for our model of the turkey elbow with its original cartilage (as acquired by 3D scanning).
DOI: 10.6084/m9.figshare.19427012.v1
title: Alligator Cartilage Reconstructed Model

description: This is the simulation file (Adams MSC) for our model of the alligator elbow with its cartilage reconstructed as we did in our <i>Dreadnoughtus </i>models.
DOI: 10.6084/m9.figshare.19426991
title: Turkey Cartilage Reconstructed Model

description: This is the simulation file (Adams MSC) for our model of the turkey elbow with cartilage reconstructed as in our <i>Dreadnoughtus </i>models.
DOI: 10.6084/m9.figshare.19426994
title: Alligator Original Cartilage Model

description: This is the simulation file (Adams MSC) for our model of the alligator elbow with its original cartilage (as acquired by 3D scanning).
DOI: 10.5281/zenodo.6599268
title: Quantification of transgene expression in GSH AAVS1 with a novel CRISPR/Cas9 based approach reveals high transcriptional variation

description: Inderbitzin, Loosli and colleagues employ a novel method to construct and extensively characterize DNA barcode libraries and apply CRISPR/Cas9 technology for targeted insertion into the safe harbor gene AAVS1 in Jurkat cells. This technique revealed high fluctuations in gene expression in AAVS1, spanning over two logs.
DOI: 10.6084/m9.figshare.19426991.v1
title: Turkey Cartilage Reconstructed Model

description: This is the simulation file (Adams MSC) for our model of the turkey elbow with cartilage reconstructed as in our <i>Dreadnoughtus </i>models.
DOI: 10.5281/zenodo.6599305
title: DUNEdn supporting data

description: A dataset containing a sample event inspired by ProtoDUNE-SP simulation.<br> Checkpoints of trained DUNEdn package models used for Springer original article.
DOI: 10.6084/m9.figshare.19426961.v1
title: Turkey Original Cartilage Model

description: This is the simulation file (Adams MSC) for our model of the turkey elbow with its original cartilage (as acquired by 3D scanning).
DOI: 10.5281/zenodo.6599304
title: DUNEdn supporting data

description: A dataset containing a sample event inspired by ProtoDUNE-SP simulation.<br> Checkpoints of trained DUNEdn package models used for Springer original article.
DOI: 10.6084/m9.figshare.12005418.v1
title: Value of reflectance confocal microscopy for the monitoring of rosacea during treatment with topical ivermectin

description: Reflectance confocal microscopy (RCM) enables noninvasive <i>Demodex</i> mite detection in rosacea. Objective scoring of rosacea severity is currently lacking. To determine the value of RCM for monitoring <i>Demodex</i>, inflammation and vascular parameters in rosacea during treatment. In 20 rosacea patients, clinical and RCM examination were performed before, during, and 12 weeks after a 16-week treatment course with topical ivermectin. Using RCM, number of mites and inflammatory cells, epidermal thickness, and vascular density and diameter were measured. RCM features were correlated with clinical assessment. Treatment resulted in clinical reduction of inflammatory lesions. Mites were detected in 80% of patients at baseline, 30% at week 16, and 63% at week 28. The number of mites reduced significantly during treatment, but no changes in inflammatory cells, epidermal thickness or vascular parameters were observed. Correlation between number of inflammatory lesions and mites was low. None of the RCM variables were significant predictors for clinical success. RCM enables anti-inflammatory effect monitoring of topical ivermectin by determining mite presence. Quantifying exact mite number, and inflammatory and vascular characteristics is challenging due to device limitations. In its current form, RCM seems of limited value for noninvasive follow-up of rosacea in clinical practice.
DOI: 10.6084/m9.figshare.12005418
title: Value of reflectance confocal microscopy for the monitoring of rosacea during treatment with topical ivermectin

description: Reflectance confocal microscopy (RCM) enables noninvasive <i>Demodex</i> mite detection in rosacea. Objective scoring of rosacea severity is currently lacking. To determine the value of RCM for monitoring <i>Demodex</i>, inflammation and vascular parameters in rosacea during treatment. In 20 rosacea patients, clinical and RCM examination were performed before, during, and 12 weeks after a 16-week treatment course with topical ivermectin. Using RCM, number of mites and inflammatory cells, epidermal thickness, and vascular density and diameter were measured. RCM features were correlated with clinical assessment. Treatment resulted in clinical reduction of inflammatory lesions. Mites were detected in 80% of patients at baseline, 30% at week 16, and 63% at week 28. The number of mites reduced significantly during treatment, but no changes in inflammatory cells, epidermal thickness or vascular parameters were observed. Correlation between number of inflammatory lesions and mites was low. None of the RCM variables were significant predictors for clinical success. RCM enables anti-inflammatory effect monitoring of topical ivermectin by determining mite presence. Quantifying exact mite number, and inflammatory and vascular characteristics is challenging due to device limitations. In its current form, RCM seems of limited value for noninvasive follow-up of rosacea in clinical practice.
DOI: 10.6084/m9.figshare.12186525
title: Mycophenolate mofetil and lichen planopilaris: systematic review and meta-analysis

description: For severe cases of lichen planopilaris (LPP), unresponsive to first line therapy, systemic or potent agents may be required for disease control. There have been several reports of the off-label use of mycophenolate mofetil (MMF) in patients with LPP or have developed adverse effects to initial agents. A systematic review and meta-analysis was performed according to recommended Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies with ≥5 cases reporting the outcomes of MMF in LPP were pooled and a meta-analysis of proportion was performed. Case reports were excluded from analysis. A total of six studies were identified and included for meta-analysis, comprising 94 LPP patients. The pooled proportion of any good response (partial or complete) was 69.2% (95% confidence interval (CI): 47.8–77). The pooled proportion of complete response was 20% (95% CI: 10.1–36.3). The pooled proportion of partial responses was 49.2% (95% CI: 30.5–63.7). Side effects occurred in 16.9% (95% CI: 17.6–33.2). of cases, which included elevated LFTs, edema, hyperlipidemia, anemia, herpes zoster infection, photosensitivity, and urinary tract infection. The current evidence for MMF remains limited. However, it appears to be a potential treatment option for patients with severe or recalcitrant LPP who have failed hydroxychloroquine and other immunosuppressants.
DOI: 10.6084/m9.figshare.12513224
title: Biologics and small molecules in patients with scalp psoriasis: a systematic review

description: Scalp psoriasis is common in psoriasis patients, difficult to treat and manifests a significant burden on quality of life. Efficacy assessment of biologics and small molecules in scalp psoriasis with reported safety and quality of life. Biological therapies and small molecules licensed for treatment of plaque psoriasis are assessed. Fourteen studies reporting results from RCTs are included. Efficacy assessment is measured through improvement of Psoriasis Scalp Severity Index (PSSI), Scalp Physician Global Assessment (ScPGA) and/or Scalp-Specific Investigator’s Global Assessment (ss-IGA). Among biologics measured by PSSI, brodalumab, secukinumab and in a subgroup ixekizumab showed high efficacy in moderate to severe scalp psoriasis. Both brodalumab and ixekizumab demonstrated rapid response within 2 weeks. Guselkumab was superior to adalimumab and ixekizumab was superior to etanercept. Apremilast showed long-term efficacy. Only few studies reported quality of life in treatment of scalp involvement which showed improvement. All treatments demonstrated acceptable safety profile. Effective treatment of scalp psoriasis is essential for improving the quality of life of psoriasis patients. Both Biologics and small molecules proved efficacy. This review may help choosing the appropriate treatment in cases where scalp psoriasis is the main complaint. A unified measurement tool for scalp psoriasis severity is needed to facilitate comparisons.
DOI: 10.6084/m9.figshare.12073230
title: Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year

description: To compare PASI outcomes of approved biologics and apremilast after 1 year of treatment. A systematic review identified RCTs and long-term extensions reporting PASI 75, 90, and 100 responses in adults with moderate-to-severe psoriasis. Data for analysis were modeled using a Bayesian multinomial likelihood model with probit link. Twenty-eight studies reporting PASI responses were included in the network meta-analysis. Differences in study design led to a stepwise approach to synthesis, consisting of two analyses. The primary analysis included nine RCTs investigating comparative efficacy at 1 year. Results indicated risankizumab, brodalumab, and guselkumab were the most effective therapies, followed by ixekizumab and secukinumab; all demonstrated superiority to ustekinumab and etanercept. The secondary analysis extended the primary analysis with 19 further studies comparing active interventions to placebo outcomes extrapolated from induction. The interventions generating the highest PASI response were the same as the primary analysis. These therapies were more effective than apremilast, ustekinumab, adalimumab, certolizumab, etanercept, and infliximab. This NMA demonstrated that evaluated IL-17 and IL-23 inhibitors outperformed other biological therapies after 1 year. Risankizumab had a higher probability of achieving PASI outcomes than all other biologics, except brodalumab and guselkumab, where no significant difference could be concluded.
DOI: 10.6084/m9.figshare.12073230.v1
title: Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year

description: To compare PASI outcomes of approved biologics and apremilast after 1 year of treatment. A systematic review identified RCTs and long-term extensions reporting PASI 75, 90, and 100 responses in adults with moderate-to-severe psoriasis. Data for analysis were modeled using a Bayesian multinomial likelihood model with probit link. Twenty-eight studies reporting PASI responses were included in the network meta-analysis. Differences in study design led to a stepwise approach to synthesis, consisting of two analyses. The primary analysis included nine RCTs investigating comparative efficacy at 1 year. Results indicated risankizumab, brodalumab, and guselkumab were the most effective therapies, followed by ixekizumab and secukinumab; all demonstrated superiority to ustekinumab and etanercept. The secondary analysis extended the primary analysis with 19 further studies comparing active interventions to placebo outcomes extrapolated from induction. The interventions generating the highest PASI response were the same as the primary analysis. These therapies were more effective than apremilast, ustekinumab, adalimumab, certolizumab, etanercept, and infliximab. This NMA demonstrated that evaluated IL-17 and IL-23 inhibitors outperformed other biological therapies after 1 year. Risankizumab had a higher probability of achieving PASI outcomes than all other biologics, except brodalumab and guselkumab, where no significant difference could be concluded.
DOI: 10.6084/m9.figshare.12186525.v1
title: Mycophenolate mofetil and lichen planopilaris: systematic review and meta-analysis

description: For severe cases of lichen planopilaris (LPP), unresponsive to first line therapy, systemic or potent agents may be required for disease control. There have been several reports of the off-label use of mycophenolate mofetil (MMF) in patients with LPP or have developed adverse effects to initial agents. A systematic review and meta-analysis was performed according to recommended Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies with ≥5 cases reporting the outcomes of MMF in LPP were pooled and a meta-analysis of proportion was performed. Case reports were excluded from analysis. A total of six studies were identified and included for meta-analysis, comprising 94 LPP patients. The pooled proportion of any good response (partial or complete) was 69.2% (95% confidence interval (CI): 47.8–77). The pooled proportion of complete response was 20% (95% CI: 10.1–36.3). The pooled proportion of partial responses was 49.2% (95% CI: 30.5–63.7). Side effects occurred in 16.9% (95% CI: 17.6–33.2). of cases, which included elevated LFTs, edema, hyperlipidemia, anemia, herpes zoster infection, photosensitivity, and urinary tract infection. The current evidence for MMF remains limited. However, it appears to be a potential treatment option for patients with severe or recalcitrant LPP who have failed hydroxychloroquine and other immunosuppressants.
DOI: 10.6084/m9.figshare.12063270
title: Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis

description: Vitiligo is an autoimmune disorder characterized by progressive loss of melanocytes, leading to cutaneous depigmentation. Vitiligo has significant psychosocial impacts on patients and is challenging to manage with limited treatment options. Recent studies have suggested promising results for JAK1/3 inhibitors including tofacitinib and ruxolitinib. To determine the expected response of vitiligo to JAK inhibitor therapy and factors which influence response rates. A systematic review and meta-analysis was performed according to PRISMA guidelines. Good response was defined as repigmentation &gt;50% or a ‘good’ or ‘excellent’ outcome as described by authors. Partial response was defined as some repigmentation &lt;50%. From the 9 eligible studies, individual patient data from 45 cases were pooled. Good response was achieved in 57.8%, partial response in 22.2%, and none or minimal response in 20% of cases. When subgrouped according to site, facial vitiligo had the highest good response rate (70%), compared to extremities (27.3%) and torso/non-sun exposed areas (13.6%). Concurrent phototherapy was significant associated with higher rates of good overall response (<i>p</i> p There is promising low-quality evidence regarding the effectiveness of JAK inhibitors in vitiligo. Concurrent UVB phototherapy appears to improve efficacy of JAK inhibitors for vitiligo.
DOI: 10.6084/m9.figshare.12162144
title: Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials

description: We evaluated the efficacy of brodalumab in patients with nail or scalp psoriasis in three phase 3 studies (AMAGINE-1/-2/-3). In AMAGINE-1, scalp clearance, measured by the psoriasis scalp severity index (PSSI), was reported for patients who received brodalumab 210 mg every 2 weeks (Q2W) or placebo through 12 weeks. In AMAGINE-2/-3, nail clearance, measured by the nail psoriasis severity index (NAPSI), was reported for patients receiving either brodalumab 210 mg Q2W or ustekinumab continuously through 52 weeks. At week 12, significantly more patients receiving brodalumab achieved 75% and 100% improvement rates from baseline PSSI and had lower mean PSSI across 12 weeks compared with placebo, with significant improvement in PSSI evident with brodalumab 210 mg Q2W vs placebo by week 2. Across 52 weeks, patients receiving brodalumab achieved significantly greater complete clearance of nail psoriasis (NAPSI 0), lower mean NAPSI, and higher mean percent improvement rates from baseline NAPSI than patients receiving ustekinumab. At week 52, 63.8% of patients receiving brodalumab achieved NAPSI 0 vs 39.1% of patients receiving ustekinumab. Brodalumab was associated with clearance of scalp psoriasis through 12 weeks and improvements in nail psoriasis, including complete nail clearance, through 52 weeks.
DOI: 10.6084/m9.figshare.12063270.v1
title: Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis

description: Vitiligo is an autoimmune disorder characterized by progressive loss of melanocytes, leading to cutaneous depigmentation. Vitiligo has significant psychosocial impacts on patients and is challenging to manage with limited treatment options. Recent studies have suggested promising results for JAK1/3 inhibitors including tofacitinib and ruxolitinib. To determine the expected response of vitiligo to JAK inhibitor therapy and factors which influence response rates. A systematic review and meta-analysis was performed according to PRISMA guidelines. Good response was defined as repigmentation &gt;50% or a ‘good’ or ‘excellent’ outcome as described by authors. Partial response was defined as some repigmentation &lt;50%. From the 9 eligible studies, individual patient data from 45 cases were pooled. Good response was achieved in 57.8%, partial response in 22.2%, and none or minimal response in 20% of cases. When subgrouped according to site, facial vitiligo had the highest good response rate (70%), compared to extremities (27.3%) and torso/non-sun exposed areas (13.6%). Concurrent phototherapy was significant associated with higher rates of good overall response (<i>p</i> p There is promising low-quality evidence regarding the effectiveness of JAK inhibitors in vitiligo. Concurrent UVB phototherapy appears to improve efficacy of JAK inhibitors for vitiligo.